Business and Finance

Will address biologics drug substance and drug product manufacturing services

Factory will reportedly provide capability of manufacturing 3-4 vaccines simultaneously

Acquisition works toward addressing needs of regenerative medicine industry

Includes a 36,000-square-foot addition to Charlottetown location

Campus will feature a CDMO, over 1,000,000 square feet of floor space

The need for supporting services in copay accumulator and best price areas

Product is powered by company’s Opus platform

Collective project expected to enhance the manufacturing supply chain for ATMPs within the UK

Aims to increase presence in affordability market

Deal features $45 million for commercialization of several Big Pharma products

Acquisition expected to be finalized in April

Among benefits, Expanded Access software can reportedly help design more effective clinical trials and capture RWD

Acquires MarketShare Movers, as company aims to provide patients with affordability services

Deal expected to help expand its API production services

Harvard Business School’s Robert S. Kaplan, co-inventor of the Balanced Scorecard offers three guiding principles of M&A execution excellence.

Expansion features 11 new cGMP labs at Durham, NC location

A chat with Cardinal Health’s Joel Wayment, who dives into what can be done to help ensure that patients receive their necessary medications, no matter the conditions

The parties are partnering up to leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies

Turnkey centers will promote scalable vaccine production for an end-to-end manufacturing network for mRNA-based vaccines in Africa

CDMO obtains both Vibalogics and Arranta Bio to increase presence in the sector

Will establish presence in Belgium, Denmark, Norway, the Netherlands, Poland and Sweden

Agreement provides pharma firms with an RWD and commercialization solution

Publication finds that only about 40% of retail pharmacists feel equipped to discuss biosimilars with patients

A conversation with Michael Abrams, co-founder and managing partner, Numerof & Associates

Examining the divestment risks, as more large companies look to spin off consumer health and other business units to focus on branded pharmaceuticals